<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20020503091502Z</creation_date><modification_date>D:20060321212021+01'00'</modification_date><initial_authorization>True</initial_authorization><pdf_file>EU-3-02-101_o_w_dec_0.pdf</pdf_file></head><body><section><header>i</header></section><section><header>en</header><p>commission of the european communitiesbrussels, 30/04/2002c(2002) 1832
 not for publication</p></section><section><header>commission decisionof 30/04/2002
 relating to the designation of medicinal product &quot;pseudomonas exotoxin (domains
 ii/iii)-interleukin 13 chimeric protein&quot; as an orphan medicinal product</header><p>only the english text is authentic.ii</p></section><section><header>commission decisionof 30/04/2002
 relating to the designation of medicinal product &quot;pseudomonas exotoxin (domains
 ii/iii)-interleukin 13 chimeric protein&quot; as an orphan medicinal product</header><p>the commission of the european communities,having regard to the treaty establishing the european community,
 having regard to regulation (ec) no 141/2000 of the european parliament and of the
 council of 16 december 1999 on orphan medicinal products
 1, and in particular article5(8) thereof,
 whereas:
 (1)</p><p>an application concerning the medicinal product “pseudomonas exotoxin
 (domains ii/iii)-interleukin 13 chimeric protein” was submitted by the sponsor
 ppd global ltd and validated on 31 january 2002 under article 5(4) of
 regulation (ec) no 141/2000.
 (2)</p><p>the medicinal product “pseudomonas exotoxin (domains ii/iii)-interleukin 13
 chimeric protein” meets the designation criteria of article 3(1) of the above-
 mentioned regulation.
 (3)</p><p>the favourable opinion of the european agency for the evaluation of medicinal
 products, adopted by the committee for orphan medicinal products on 26 march
 2002, was received by the commission on 28 march 2002,
 has adopted this decision:
 article 1the medicinal product “pseudomonas exotoxin (domains ii/iii)-interleukin 13 chimericprotein” is hereby designated as an orphan medicinal product for the orphan indication:
 treatment of glioma. it shall be entered in the community register of orphan medicinal
 products under the number eu/3/02/101.</p><p> 
 1 oj l 18, 22.1.2000, p.1iiiarticle 2the european agency for the evaluation of medicinal products shall provide to allinterested parties the opinion of the committee for orphan medicinal products referred
 to in this decision.
 article 3this decision is addressed to the sponsor ppd global ltd, granta park, great abington,cambridge, cambridgeshire cb1 6gq, united kingdom.
 done at brussels, 30/04/2002
 for the commissionerkki liikanen
 member of the commission</p></section></body></xml>